Protective effects of NSAIDs on the development of Alzheimer disease

Neurology

Volumn 70, Issue 19 PART 1, 2008, Pages 1672-1677

  Vlad, Steven C ^a,c   Miller, Donald R ^b,c   Kowall, Neil W ^a,c   Felson, David T ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARYLPROPIONIC ACID DERIVATIVE; CELECOXIB; CHOLINE SALICYLATE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIFLUNISAL; ETODOLAC; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MAGNESIUM; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; ROFECOXIB; SALICYLIC ACID DERIVATIVE; SALSALATE; SULINDAC; TOLMETIN; VALDECOXIB;

AGED; ALZHEIMER DISEASE; ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; FEMALE; HEALTH CARE SYSTEM; HUMAN; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUROPROTECTION; POPULATION RESEARCH; PRIORITY JOURNAL; RACE; RISK ASSESSMENT; TREATMENT DURATION; VETERAN;

EID: 43149102747     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000311269.57716.63     Document Type: Article

References (17)

1. BA in t’ Veld A Ruitenberg A Hofman Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease N Engl J Med 345 2001 1515 1521
2. EE Tuppo HR Arias The role of inflammation in Alzheimer's disease Int J Biochem Cell Biol 37 2005 289 305
3. AJM de Craen J Gussekloo B Vrijsen RGJ Westendorp Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia Am J Epidemiol 161 2005 114 120
4. PS Aisen KA Schafer M Grundman Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial JAMA 289 2003 2819 2826
5. SA Reines GA Block JC Morris Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study Neurology 62 2004 66 71
6. S Scharf A Mander A Ugoni F Vajda N Christophidis A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease Neurology 53 1999 197 201
7. PS Aisen J Schmeidler GM Pasinetti Randomized pilot study of nimesulide treatment in Alzheimer's disease Neurology 58 2002 1050 1054
8. J Rogers LC Kirby SR Hempelman Clinical trial of indomethacin in Alzheimer's disease Neurology 43 1993 1609 1611
9. ADAPT Research Group Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial Neurology 68 2007 1800 1808
10. L Gasparini E Ongini G Wenk Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action J Neurochem 91 2004 521 536
11. T Morihara B Teter F Yang Ibuprofen suppresses interleukin-1β induction of pro-amyloidogenic α1-antichymotrypsin to ameliorate β-amyloid (Aβ) pathology in Alzheimer's models Neuropsychopharmacology 30 2005 1111 1120
12. L Gasparini E Ongini D Wilcock D Morgan Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease Brain Res Brain Res Rev 48 2005 400 408
13. 1-42 secretion J Med Chem 48 2005 5705 5720
14. JL Eriksen SA Sagi TE Smith NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Aβ 42 in vivo J Clin Invest 112 2003 440 449
15. DR Miller MM Safford LM Pogach Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data Diabetes Care 27 suppl 2 2004 B10 B21
16. F Giuliano JA Mitchell TD Warner Sodium salicylate inhibits prostaglandin formation without affecting the induction of cyclooxygenase-2 by bacterial lipopolysaccharide in vivo J Pharmacol Exp Ther 299 2001 894 900
17. L Letenneur S Larrieu P Barberger-Gateau Alcohol and tobacco consumption as risk factors of dementia: a review of epidemiological studies Biomed Pharmacother 58 2004 95 99